Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Arthritis, Rheumatoid 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Colorectal Neoplasms 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Standard of Care 3Educational Status 2vilanterol 1tocilizumab 1perflutren 1X-Rays 1Tiotropium Bromide 1Therapeutics 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Sulfur Hexafluoride 1Specimen Handling 1Singing 1Salmeterol Xinafoate 1Rehabilitation 1Pulmonary Surgical Procedures 1Prednisolone 1Practice Guidelines as Topic 1Pharmacists 1Methods 1Massage 1Magnesium Sulfate 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Iloprost 1Hypnosis 1Hematologic Tests 1Geritol 1General Practitioners 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pulmonary Disease, Chronic Obstructive × tocilizumab × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡